Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Summary

This randomised, double-blinded, placebo-controlled study aims to establish metabolic improvements in subjects diagnosed with Alzheimer's Disease (AD) by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine. Participants will take the drug CMA2 or a placebo twice a day for 26 weeks. They will visit the clinic 4 times for checkups and tests.

Timeline

Start

2025-09-12

Primary completion

2026-09

Completion

2026-09

Drugs

Indications